SCHEMBL3872649

SCHEMBL3872649

CN(Cc1cccc(C(=O)NC2CCCCC2)c1)S(=O)(=O)c1cc2ccccc2s1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
HSD17B10 Q99714 2/20 0.49
RAB9A P51151 7/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 1/20 0.47
GFER P55789 1/20 0.47
CTSD P07339 1/20 0.47
BACE1 P56817 1/20 0.47
MAPK1 P28482 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
HPGD P15428 1/20 0.43
OPRM1 P35372 1/20 0.42
MAOB P27338 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882723 0.88 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2NPC1MEN1
SCHEMBL3886237 0.83 TRPM8 (0.49) ALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL3872646 0.82 HSD11B1 (0.50) ALDH1A1LMNAHSD17B10RAB9ASMN1; SMN2
SCHEMBL3879724 0.82 ALDH1A1 (0.57) ALDH1A1LMNAHSD17B10RAB9ASMN1; SMN2
SCHEMBL3879707 0.81 RAB9A (0.53) ALDH1A1LMNARAB9ASMN1; SMN2NPC1
SCHEMBL3887293 0.80 MAPT (0.49) ALDH1A1LMNARAB9ASMN1; SMN2NPC1
SCHEMBL3876863 0.78 NR1H4 (0.49) ALDH1A1LMNAHSD17B10RAB9ASMN1; SMN2
SCHEMBL3872157 0.78 PPARG (0.45) ALDH1A1LMNARAB9ASMN1; SMN2NPC1
SCHEMBL3881153 0.78 ALDH1A1 (0.51) ALDH1A1LMNAHSD17B10RAB9ASMN1; SMN2
SCHEMBL3872970 0.78 ROCK2 (0.45) ALDH1A1LMNAHSD17B10RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 ALDH1A1 210/4885LMNA 2473/4885HSD17B10 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.